Nephropathy in Type 2 Diabetes: Effects of an Intensive Multifactorial Intervention Trial on Cardio-renal Events.
Latest Information Update: 18 Sep 2021
Price :
$35 *
At a glance
- Drugs Amlodipine; Aspirin; Atenolol; Clonidine; Doxazosin; Erythropoietins; Fibric acid derivatives; Furosemide; Hydrochlorothiazide; Insulin; Irbesartan; Ramipril; Simvastatin
- Indications Cardiovascular disorders; Diabetic nephropathies
- Focus Therapeutic Use
- Acronyms NID-2
- 03 Aug 2020 Biomarkers information updated
- 20 Dec 2011 Planned end date changed from 1 Dec 2010 to 1 Sep 2012 as reported by ClinicalTrials.gov.
- 08 Oct 2007 New trial record.